About IO Biotech

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and severa

Company Highlights
Year Founded

2015

icon-altEmployees

87

Location (HQ)

DNK

Since Last Funding

1 year 1 month

Monthly Website Visitors

14.1K

icon-altTotal Investment Amt

$200M

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

3.57%

icon-altYoY Headcount Growth

29.81%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Therapeutics

Health Care

Biotechnology Research

Biotechnology